IL144345A0 - Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors - Google Patents
Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitorsInfo
- Publication number
- IL144345A0 IL144345A0 IL14434500A IL14434500A IL144345A0 IL 144345 A0 IL144345 A0 IL 144345A0 IL 14434500 A IL14434500 A IL 14434500A IL 14434500 A IL14434500 A IL 14434500A IL 144345 A0 IL144345 A0 IL 144345A0
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- tace
- mmp
- tnf
- preparation
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 102000043279 ADAM17 Human genes 0.000 title 1
- 108091007505 ADAM17 Proteins 0.000 title 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 125000000304 alkynyl group Chemical group 0.000 title 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23803899A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/001864 WO2000044723A1 (en) | 1999-01-27 | 2000-01-27 | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL144345A0 true IL144345A0 (en) | 2002-05-23 |
Family
ID=22896246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14434500A IL144345A0 (en) | 1999-01-27 | 2000-01-27 | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JP2002535390A (cs) |
| KR (1) | KR20010101732A (cs) |
| AR (1) | AR035312A1 (cs) |
| AT (1) | ATE309986T1 (cs) |
| AU (1) | AU769418B2 (cs) |
| CA (1) | CA2356313A1 (cs) |
| CZ (1) | CZ20012711A3 (cs) |
| DE (1) | DE60024056D1 (cs) |
| EA (1) | EA200100806A1 (cs) |
| HU (1) | HUP0200223A3 (cs) |
| IL (1) | IL144345A0 (cs) |
| NZ (1) | NZ512566A (cs) |
| ZA (1) | ZA200105222B (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1577299A1 (en) * | 2002-12-26 | 2005-09-21 | Carna Biosciences Inc. | Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient |
| JP2009542666A (ja) * | 2006-06-30 | 2009-12-03 | シェーリング コーポレイション | Ｐ５３活性を増加させる置換ピペリジンおよびその使用 |
| KR20110022635A (ko) * | 2008-06-02 | 2011-03-07 | 시플라 리미티드 | 레보세티리진의 합성방법 및 이에 사용하기 위한 중간체 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE04295B1 (et) * | 1997-02-27 | 2004-06-15 | American Cyanamid Company | N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül-, -sulfinüül- või-sulfonüül-)-3-asendatud-alküülamiidid, -arüülamiidid või -heteroarüülamiididkui maatriksmetalloproteinaasi inhibiitorid |
| GEP20022797B (en) * | 1998-02-19 | 2002-09-25 | American Cyanamid Co | N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl Sulfanyl, Sulfinil or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase Inhibitors |
-
2000
- 2000-01-26 AR ARP000100327A patent/AR035312A1/es not_active Application Discontinuation
- 2000-01-27 IL IL14434500A patent/IL144345A0/xx unknown
- 2000-01-27 AT AT00904569T patent/ATE309986T1/de not_active IP Right Cessation
- 2000-01-27 CZ CZ20012711A patent/CZ20012711A3/cs unknown
- 2000-01-27 JP JP2000595979A patent/JP2002535390A/ja active Pending
- 2000-01-27 DE DE60024056T patent/DE60024056D1/de not_active Expired - Lifetime
- 2000-01-27 NZ NZ512566A patent/NZ512566A/xx unknown
- 2000-01-27 AU AU26305/00A patent/AU769418B2/en not_active Ceased
- 2000-01-27 HU HU0200223A patent/HUP0200223A3/hu unknown
- 2000-01-27 CA CA002356313A patent/CA2356313A1/en not_active Abandoned
- 2000-01-27 KR KR1020017009432A patent/KR20010101732A/ko not_active Application Discontinuation
- 2000-01-27 EA EA200100806A patent/EA200100806A1/ru unknown
-
2001
- 2001-06-25 ZA ZA200105222A patent/ZA200105222B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20012711A3 (cs) | 2002-05-15 |
| JP2002535390A (ja) | 2002-10-22 |
| HUP0200223A2 (en) | 2002-06-29 |
| CA2356313A1 (en) | 2000-08-03 |
| AU2630500A (en) | 2000-08-18 |
| ZA200105222B (en) | 2002-09-25 |
| NZ512566A (en) | 2004-02-27 |
| HUP0200223A3 (en) | 2002-12-28 |
| ATE309986T1 (de) | 2005-12-15 |
| EA200100806A1 (ru) | 2002-08-29 |
| AR035312A1 (es) | 2004-05-12 |
| DE60024056D1 (de) | 2005-12-22 |
| KR20010101732A (ko) | 2001-11-14 |
| AU769418B2 (en) | 2004-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0000641A3 (en) | Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them | |
| ZA9811112B (en) | Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors. | |
| AU2003282920A8 (en) | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
| AU2002341715A1 (en) | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
| PL349900A1 (en) | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | |
| ZA979238B (en) | The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors. | |
| NZ304689A (en) | Lactam-containing hydroxamic acid derivatives and use as matrix metalloprotease (mmp) inhibitors | |
| AU2003220401A8 (en) | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases | |
| HUP0200119A2 (en) | Sulfamato hydroxamic acid metalloprotease inhibitor | |
| HK1045501A1 (zh) | 作為基質金屬蛋白酶抑制劑的異羥肟酸衍生物 | |
| AU6764400A (en) | Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors | |
| HUP0105302A3 (en) | 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors, their use and process for their preparation | |
| NO20013678D0 (no) | Alkynyl-holdige hydroksamsyre-derivater, deres fremstilling og deres anvendelse sommatriksmetalloproteinase(MMP)inhibitorer/TNF-<alfa>-konverteringsenzym(TACE)inhibitorer | |
| HK1037611A1 (en) | Alkynyl containing hydroxamic acid compounds as tace inhibitors. | |
| AU2002346729A1 (en) | Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases | |
| AU2202101A (en) | Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors | |
| PL357084A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | |
| IL144345A0 (en) | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors | |
| IL143713A0 (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases | |
| SI1036062T1 (en) | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors | |
| SI1147080T1 (en) | Alkynyl containing hydroxamic acid compounds as tace inhibitors | |
| AU2002359347A1 (en) | Beta-sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
| AU2003304456A1 (en) | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | |
| SI1144368T1 (en) | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | |
| SI1147101T1 (en) | Reverse hydroxamate inhibitors of matrix metalloproteinases |